MA40985A - Méthodes de traitement de la sclérose en plaques - Google Patents

Méthodes de traitement de la sclérose en plaques

Info

Publication number
MA40985A
MA40985A MA040985A MA40985A MA40985A MA 40985 A MA40985 A MA 40985A MA 040985 A MA040985 A MA 040985A MA 40985 A MA40985 A MA 40985A MA 40985 A MA40985 A MA 40985A
Authority
MA
Morocco
Prior art keywords
multiple sclerosis
treatment methods
sclerosis treatment
methods
treatment
Prior art date
Application number
MA040985A
Other languages
English (en)
Inventor
Mark Novas
Rui Zhang (Ray)
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA40985A publication Critical patent/MA40985A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA040985A 2014-11-17 2015-11-15 Méthodes de traitement de la sclérose en plaques MA40985A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080783P 2014-11-17 2014-11-17
US201562140255P 2015-03-30 2015-03-30
US201562232963P 2015-09-25 2015-09-25

Publications (1)

Publication Number Publication Date
MA40985A true MA40985A (fr) 2017-09-26

Family

ID=54771192

Family Applications (2)

Application Number Title Priority Date Filing Date
MA040985A MA40985A (fr) 2014-11-17 2015-11-15 Méthodes de traitement de la sclérose en plaques
MA053882A MA53882A (fr) 2014-11-17 2015-11-16 Méthodes de traitement de la sclérose en plaques

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053882A MA53882A (fr) 2014-11-17 2015-11-16 Méthodes de traitement de la sclérose en plaques

Country Status (13)

Country Link
US (8) US20170354630A1 (fr)
EP (3) EP4215191A1 (fr)
JP (4) JP6786486B2 (fr)
KR (3) KR102299842B1 (fr)
CN (6) CN113368091A (fr)
AU (3) AU2015350213A1 (fr)
CA (1) CA2967619C (fr)
EA (1) EA038370B1 (fr)
IL (2) IL269885B (fr)
MA (2) MA40985A (fr)
MX (1) MX2017006473A (fr)
WO (1) WO2016081355A1 (fr)
ZA (1) ZA201703207B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
SG10201907291QA (en) 2015-02-08 2019-09-27 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
AU2017240747B2 (en) 2016-04-01 2021-10-21 NOHMs Technologies, Inc. Modified ionic liquids containing phosphorus
EP3656010A4 (fr) 2017-07-17 2021-08-11 Nohms Technologies, Inc. Électrolytes contenant du phosphore
CA3175830A1 (fr) 2019-04-17 2020-10-22 Sundeep Dugar Promedicaments a base de monomethylfumarate
US20220087942A1 (en) * 2019-05-31 2022-03-24 Curacle Co., Ltd. Enteric tablet containing dimethyl fumarate
CN111440771A (zh) * 2020-03-17 2020-07-24 中山大学附属第三医院 一种含有clcn2纯合突变的白质脑病患者特异诱导多能干细胞系
AU2021208602A1 (en) 2020-05-06 2022-12-15 Imcyse Sa Combination treatment for fumarate-related diseases
KR20220075119A (ko) * 2020-11-27 2022-06-07 주식회사 뷰노 의료 영상 기반의 뇌백질 병변 탐지 방법
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
EP2801354B1 (fr) 2004-10-08 2017-02-08 Forward Pharma A/S Compositions pharmaceutiques à libération contrôlée comportant un ester d'acide fumarique
JP2009528359A (ja) * 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
PL2139467T3 (pl) * 2007-02-08 2017-08-31 Biogen Ma Inc. Neuroprotekcja w chorobach demielinizacyjnych
PT2334378E (pt) 2008-08-19 2014-07-16 Xenoport Inc Pró-fármacos de metil fumarato de hidrogénio, composições farmacêuticas dos mesmos, e métodos de utilização
HUE060312T2 (hu) 2010-01-11 2023-02-28 Biogen Ma Inc A JC vírus antitestek vizsgálata
JP2014515373A (ja) * 2011-05-26 2014-06-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法
FI3575792T3 (fi) 2011-05-31 2023-03-17 Pml-riskin arviointimenetelmä
WO2013119677A1 (fr) 2012-02-07 2013-08-15 Biogen Idec Ma Inc. Compositions pharmaceutiques contenant du fumarate de diméthyle
US20140057918A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
WO2014071371A1 (fr) 2012-11-05 2014-05-08 Xenoport, Inc. Cocristaux de méthyl(2e)but-2-ène-1,4-dioate de (n,n‑diéthylcarbamoyl)méthyle
JP6506174B2 (ja) 2012-12-21 2019-04-24 バイオジェン エムエー インコーポレイテッド 重水素置換されたフマル酸誘導体
EP2934507B1 (fr) 2012-12-21 2017-05-31 ratiopharm GmbH Promédicaments du fumarate de monométhyle (mmf)
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US20140322252A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
EP3027767A1 (fr) 2013-08-01 2016-06-08 XenoPort, Inc. Procédés d'administration de fumarate de monométhyle et promédicaments à effets secondaires réduits le contenant
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
DK3110408T3 (en) 2014-02-28 2019-04-29 Banner Life Sciences Llc ENTERY SOFT CAPS OF CONTROLLED RELEASE FUMAR TESTERS
US10391160B2 (en) 2014-03-14 2019-08-27 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
WO2016057133A1 (fr) 2014-10-08 2016-04-14 Banner Life Sciences Llc Capsules molles entériques à libération contrôlée d'esters de fumarate
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2017040272A1 (fr) 2015-08-31 2017-03-09 Banner Life Sciences Llc Formes posologiques d'ester de fumarate
WO2017151184A1 (fr) 2016-02-29 2017-09-08 Banner Life Sciences Llc Formes posologiques d'ester de fumarate
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Also Published As

Publication number Publication date
US11007167B2 (en) 2021-05-18
US20170354630A1 (en) 2017-12-14
US11007166B2 (en) 2021-05-18
AU2015350213A1 (en) 2017-05-25
KR102299842B1 (ko) 2021-09-09
US20210315854A1 (en) 2021-10-14
IL252296A0 (en) 2017-07-31
US11246850B2 (en) 2022-02-15
KR20210111362A (ko) 2021-09-10
MA53882A (fr) 2021-12-08
US20200345679A1 (en) 2020-11-05
US20210023040A1 (en) 2021-01-28
MX2017006473A (es) 2018-01-30
EP4215191A1 (fr) 2023-07-26
KR20170084270A (ko) 2017-07-19
US20180000770A1 (en) 2018-01-04
NZ731528A (en) 2021-11-26
US10959972B2 (en) 2021-03-30
US20170368013A1 (en) 2017-12-28
AU2021269298A1 (en) 2021-12-09
AU2020239734A1 (en) 2020-10-15
JP6786486B2 (ja) 2020-11-18
ZA201703207B (en) 2021-08-25
EP3220907A1 (fr) 2017-09-27
EA038370B1 (ru) 2021-08-17
EA201791101A1 (ru) 2017-12-29
WO2016081355A1 (fr) 2016-05-26
CN113368091A (zh) 2021-09-10
CN115501218A (zh) 2022-12-23
JP2022168243A (ja) 2022-11-04
IL269885B (en) 2022-06-01
CN115531366A (zh) 2022-12-30
JP2017537089A (ja) 2017-12-14
IL252296B (en) 2022-06-01
CA2967619A1 (fr) 2016-05-26
US20190125710A1 (en) 2019-05-02
CN107106530A (zh) 2017-08-29
KR20240035912A (ko) 2024-03-18
JP6830941B2 (ja) 2021-02-17
CN113368093A (zh) 2021-09-10
EP3804711A1 (fr) 2021-04-14
CN113368092A (zh) 2021-09-10
CA2967619C (fr) 2022-06-28
US11129806B2 (en) 2021-09-28
JP2020196760A (ja) 2020-12-10
US20190008817A1 (en) 2019-01-10
JP2019023248A (ja) 2019-02-14

Similar Documents

Publication Publication Date Title
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA53882A (fr) Méthodes de traitement de la sclérose en plaques
GB201701673D0 (en) Methods of well treatment
DK3590543T3 (da) Medicinsk forbinding
DK3851537T3 (da) Behandling af hyperbilirubinæmi
BR112017018413A2 (pt) tratamento de pancreatite
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
SG11201609652RA (en) Treatment of polybacterials infections
SG11201702688UA (en) Methods of treating rsv infections
DK3231444T3 (da) Ny behandling
IL256207B (en) Methods for treating multiple sclerosis
DK3393579T3 (da) Øjenbehandlingssystem
DK3203834T3 (da) Hovbehandlingsarrangement
BR112018000204A2 (pt) métodos de tratamento de colite
GB201416832D0 (en) Methods of treatment
MA40687A (fr) Méthodes et compositions de traitement de malformation vasculaire
BR112016015712A2 (pt) método de tratamento de doenças hepáticas.
BR112017011897A2 (pt) métodos de tratamento da fibrose
FR3022129B1 (fr) Baignoire de puericulture
DK3200783T3 (da) Behandling af erytromelalgi
FR3024647B1 (fr) Transat de puericulture
ITUB20153349A1 (it) Macchina di trattamento di superfici
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201512139D0 (en) Methods of treatment
DK3250168T3 (da) Forbedringer vedrørende nethindebehandling